Tissue specific tumour transition needs few cellsGerman researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells. more ➔
Drug dissociates metastasis precursors in bloodA team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated … more ➔
Policymakers take no action after ECJ mutagenesis rulingIn summer the European Court of Justice (ECJ) ruled that crops created by biological mutagenesis techniques fall under EU GMO legislation. Germany’s government and the European Parliament see no need … more ➔
Sandoz’ antiinfectives partner Ares Genetics gets fundJust in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed … more ➔
AI provides face read-out of genetic diseasesExperts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from … more ➔
Sanofi ends immuno-oncology discovery with RegeneronSanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab … more ➔
Diverse cells make up the endotheliumCells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science. more ➔
Microbiome defines gut conditionsDifferences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report. more ➔
Cellestia Biotech AG attracts Series A financingCancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing. more ➔
Staten Biotechnology in $430m deal with Novo NordiskStaten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk. more ➔
